Aurobindo Pharma Ltd.
NSE: AUROPHARMAAurobindo Pharma Ltd.: A 30-second snapshot
Aurobindo Pharma trades at ₹1576.30, up 40.92% over the past year and within 3.7% of its 52-week high, sitting above both its 50-day (₹1510.19) and 200-day (₹1311.33) moving averages with an RSI of 56.56 (neutral). Trailing PE is 26.18x (forward PE 17.49x) against a debt-to-equity of roughly 0.21x; ROE (9.93%) has not exceeded 15% in any tracked year and free cash flow was positive in only 2 of those years. Mean analyst rating is 2.07 across 29 analysts (1-5 scale, lower = more constructive).
P/E
26.2
Forward P/E
17.5
ROE
+9.9%
Debt / Equity
21.31
Profit Margin
+10.4%
Div. Yield
+0.3%
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
54/100
News
8 headlines · 0 positive · 2 negative
Aurobindo Pharma Q1 Results: Earnings call scheduled for Aug 6 - scanx.trade
scanx.trade
Indian pharma seeks engagement with the US administration after Trump's generic drug tariff plan - Business Today
Business Today
Pharma Stocks Tumble as Trump Unveils 200% Tariff Plan on Generics - HDFC Sky
HDFC Sky
Sun Pharma, Aurobindo, Lupin, Zydus Life shares: Analyst views on Trump's generic tariff roadmap - Business Today
Business Today
Aurobindo Pharma Transfers Domestic Branded Generics Business to Wholly Owned Arm Auropharm - Medical Dialogues
Medical Dialogues
Recent context
- ·Aurobindo's Q1 results earnings call is scheduled for Aug 6, 2026 (scanx.trade, Jul 29).
- ·Coverage the week of Jul 22 centered on a proposed US 200% tariff plan on generic drugs, reported as a sector-wide story affecting Sun Pharma, Aurobindo, Lupin and Zydus Life collectively, with Indian pharma industry bodies seeking engagement with the US administration (Business Today, HDFC Sky).
- ·Aurobindo transferred its domestic branded-generics business to a wholly owned subsidiary, Auropharm, per a Jul 3 report (Medical Dialogues).
Strengths
- +Trailing PE of 26.18x is the lowest among its 6-stock pharma peer set (peers range 28.9x-74.6x), ranking 1st of 6 on this metric.
- +Price trades above both the 50-day (₹1510.19) and 200-day (₹1311.33) moving averages, up 40.92% over the past year and 10.38% over the past 3 months.
- +Forward PE of 17.49x is well below the trailing 26.18x, consistent with consensus estimates pointing to near-term earnings improvement.
- +Debt-to-equity is approximately 0.21x in absolute terms (raw metric 21.31, percent-scaled).
Weaknesses
- −Free cash flow was positive in only 2 of the tracked years (negative in the remaining 3), alongside a rising debt trend flagged in the persistence data.
- −ROE has not exceeded 15% in any tracked year (currently 9.93%), with profit margin at 10.41% and a consistency score of 39/100.
- −Quality score of 41/100 ranks 3rd of 6 in the pharma peer set and ROE ranks 4th of 6 (Sun Pharma 14.72%, Apollo Hospitals 21.5% vs Aurobindo 9.93%).
- −Dividend yield is modest at 0.25%, and 5-year revenue growth (5.6%) and earnings growth (1.9%) have both been low.
Open questions
- ?Does the rising debt trend alongside FCF positive in only 2 of the tracked years reflect capex tied to capacity expansion, or a broader cash-conversion pattern worth tracking?
- ?How would a US generic-drug tariff, if enacted, flow through to Aurobindo's US-exposed revenue relative to peers like Sun Pharma, Lupin and Zydus Life?
- ?What would need to change in ROE and margin trends for the quality score (41/100, mid-pack among peers) to move toward peer leaders such as Sun Pharma (56)?
- ?Does the gap between forward PE (17.49x) and trailing PE (26.18x) reflect a specific near-term earnings catalyst, or a broader re-rating assumption embedded in consensus estimates?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| AUROPHARMA | Aurobindo Pharma Ltd.You're viewing | 26.2 | +9.9% | 41 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹1,576.30
SMA 50
₹1,510.19
SMA 200
₹1,311.33
RSI (14)
56.6 (neutral)
From 52w high
-3.7%
1Y return
+40.9%
3M return
+10.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highFree cash flow was positive in only 2 of the tracked years (implying negative FCF in the remaining 3), alongside a debt trend classified as rising. Absolute leverage itself remains contained: debt-to-equity is approximately 0.21x once the raw metric (21.31) is read correctly as a percent-scaled figure rather than an x-multiple.
- mediumROE has not exceeded 15% in any of the tracked years (current ROE 9.93%, profit margin 10.41%), with a consistency score of 39/100 and quality score of 41/100 that ranks 3rd of 6 pharma peers; ROE ranks 4th of 6, trailing Sun Pharma (14.72%) and Apollo Hospitals (21.5%).
- lowOf 8 tracked news items, the 2 negative-sentiment items trace to sector-wide coverage of a proposed US 200% tariff on generic drugs affecting multiple pharma names (Sun Pharma, Aurobindo, Lupin, Zydus Life) rather than Aurobindo-specific developments; company-specific headlines (Q1 earnings call, domestic branded-generics transfer to a wholly owned subsidiary) were neutral.
Cross-section contradictions
- Price is up 40.92% over 1 year and sits within 3.7% of its 52-week high, trading above both the 50-day and 200-day moving averages, while persistence data shows ROE has not exceeded 15% in any tracked year and FCF was positive in only 2 of the tracked years — price strength is not corroborated by the underlying quality/persistence metrics.
- Forward PE of 17.49x is well below the trailing PE of 26.18x, implying materially higher near-term earnings growth than the 5-year historical earnings CAGR of 1.9% suggests.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 12 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Aug 2026 · rotates through NIFTY 500 every ~5 days